States To Investigate Vytorin Marketing Ploys

By Erin Marie Daly

Law360, New York (January 29, 2008, 12:00 AM ET) -- Merck & Co. and Schering-Plough Corp. face a rising tide of controversy over Vytorin, as the attorneys general of two states investigate whether the companies suppressed the results of a study that found that the drug worked no better than an older, cheaper drug to prevent the buildup of arterial plaque.

The first slap in the face came Monday, when New York Attorney General Andrew Cuomo subpoenaed the two companies for documents and information to determine whether they purposely withheld the results of the so-called Enhance...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles